LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) from a buy rating to a neutral rating in a research report report published on Wednesday morning, Marketbeat reports.
A number of other brokerages also recently weighed in on MRNS. Robert W. Baird reaffirmed a neutral rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. HC Wainwright reissued a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Truist Financial reaffirmed a buy rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $12.75.
Check Out Our Latest Research Report on Marinus Pharmaceuticals
Marinus Pharmaceuticals Stock Up 4.5 %
Institutional Investors Weigh In On Marinus Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC raised its stake in Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after buying an additional 990,607 shares during the last quarter. Franklin Resources Inc. increased its position in Marinus Pharmaceuticals by 1.3% during the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after acquiring an additional 49,589 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares during the period. Acadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals in the second quarter worth about $813,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $727,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading
- Five stocks we like better than Marinus Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Walmart Stock: Buy the Rip or Wait for the Dip?
- How to Invest in Small Cap Stocks
- 3 Stocks to Buy for a Soft Landing, If There Is One
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.